Adiponectin in Obese Women With T2DN and Effects by RAS Blocker

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

Insulin resistance typically characterizes type 2 diabetes (T2DM) and prediabetic states and is the prominent feature of the metabolic syndrome.Adiponectin plays an important part in glucose metabolism,insulin resistance, the deterioration of renal function.we hypothesize there is a difference serum adiponectin levels between obese and non-obese women with type 2 diabetic nephropathy. Furthermore, these two groups would respond difference to the RAs blocker(Losartan).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Jiao Tong University School of Medicine
• Treatments: Angiotensin II Type 1 Receptor Blockers; Losartan

Criteria

Inclusion Criteria:

• Type 2 diabetic nephropathy

• CKD at stage 1~4

Exclusion Criteria:

• Type 1 diabetes or nondiabetic renal disease

• An elevated plasma K level.